China SXT Pharmaceuticals (SXTC)
(Delayed Data from NSDQ)
$1.13 USD
-0.11 (-8.87%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $1.13 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for China SXT Pharmaceuticals, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 17 | 16 | 13 | 7 |
Receivables | NA | 1 | 3 | 5 | 5 |
Notes Receivable | NA | 0 | 2 | 2 | 2 |
Inventories | NA | 1 | 1 | 1 | 1 |
Other Current Assets | NA | 0 | 1 | 3 | 5 |
Total Current Assets | NA | 20 | 22 | 23 | 20 |
Net Property & Equipment | NA | 1 | 2 | 2 | 2 |
Investments & Advances | NA | 9 | 9 | 9 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 30 | 34 | 35 | 22 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 2 |
Current Portion Long-Term Debt | NA | 3 | 2 | 0 | 7 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 4 | 3 | 2 |
Income Taxes Payable | NA | 1 | 1 | 1 | 1 |
Other Current Liabilities | NA | 5 | 9 | 13 | 0 |
Total Current Liabilities | NA | 15 | 17 | 19 | 12 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 15 | 17 | 19 | 12 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 0 | 0 | 0 |
Capital Surplus | NA | 36 | 31 | 25 | 17 |
Retained Earnings | NA | -22 | -16 | -10 | -7 |
Other Equity | NA | 0 | 1 | 1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 15 | 16 | 16 | 9 |
Total Liabilities & Shareholder's Equity | NA | 30 | 34 | 35 | 22 |
Total Common Equity | 0 | 15 | 16 | 16 | 9 |
Shares Outstanding | 0.40 | 0.40 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 0.00 | 36.73 | 16.42 | 15.96 | 9.40 |
Fiscal Year End for China SXT Pharmaceuticals, Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,988 | -99,999 |
Receivables | NA | NA | NA | 1 | NA |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | NA | 0 | NA |
Other Current Assets | NA | NA | NA | 0 | NA |
Total Current Assets | NA | NA | NA | 14 | NA |
Net Property & Equipment | NA | NA | NA | 1 | NA |
Investments & Advances | NA | NA | NA | NA | NA |
Other Non-Current Assets | NA | NA | NA | NA | NA |
Deferred Charges | NA | NA | NA | NA | NA |
Intangibles | NA | NA | NA | 0 | NA |
Deposits & Other Assets | NA | NA | NA | NA | NA |
Total Assets | NA | NA | NA | 15 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | NA | 1 | NA |
Current Portion Long-Term Debt | NA | NA | NA | 3 | NA |
Current Portion Capital Leases | NA | NA | NA | NA | NA |
Accrued Expenses | NA | NA | NA | 3 | NA |
Income Taxes Payable | NA | NA | NA | 1 | NA |
Other Current Liabilities | NA | NA | NA | 1 | NA |
Total Current Liabilities | NA | NA | NA | 9 | NA |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | NA | NA | NA |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | 0 | NA |
Non-Current Capital Leases | NA | NA | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | NA | NA | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | NA | 10 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | NA | 1 | NA |
Capital Surplus | NA | NA | NA | 36 | NA |
Retained Earnings | NA | NA | NA | -31 | NA |
Other Equity | NA | NA | NA | -1 | NA |
Treasury Stock | NA | NA | NA | NA | NA |
Total Shareholder's Equity | NA | NA | NA | 5 | NA |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 15 | NA |
Total Common Equity | 0 | 0 | 0 | 100,004 | 0 |
Shares Outstanding | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 250,010.20 | 0.00 |